160 related articles for article (PubMed ID: 32734463)
1. Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer.
Björnebo L; Olsson H; Nordström T; Jäderling F; Grönberg H; Eklund M; Lantz A
World J Urol; 2021 Jun; 39(6):1797-1804. PubMed ID: 32734463
[TBL] [Abstract][Full Text] [Related]
2. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
4. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
[TBL] [Abstract][Full Text] [Related]
5. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Ratnani P; Dovey Z; Parekh S; Sobotka S; Shukla D; Davis A; Roshandel R; Wagaskar V; Jambor I; Lundon DJ; Wiklund P; Kyprianou N; Menon M; Tewari A
Prostate; 2022 Jun; 82(9):970-983. PubMed ID: 35437769
[TBL] [Abstract][Full Text] [Related]
6. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
7. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
[TBL] [Abstract][Full Text] [Related]
9. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
10. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
[TBL] [Abstract][Full Text] [Related]
11. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
Chung DY; Koh DH; Goh HJ; Kim MS; Lee JS; Jang WS; Choi YD
BMC Cancer; 2018 Nov; 18(1):1057. PubMed ID: 30382916
[TBL] [Abstract][Full Text] [Related]
13. Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings.
Lantz A; Falagario UG; Ratnani P; Jambor I; Dovey Z; Martini A; Lewis S; Lundon D; Nair S; Phillip D; Haines K; Cormio L; Carrieri G; Kryprianou N; Tewari A
Eur Urol Oncol; 2022 Apr; 5(2):187-194. PubMed ID: 32891599
[TBL] [Abstract][Full Text] [Related]
14. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
15. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
16. [Pathology findings after radical prostatectomy for prostate cancer in patients eligible for active surveillance: Contribution of multiparametric MRI to treatment decision].
Martin-Malburet A; Marcq G; Leroy X; Guiffart P; Fantoni JC; Flamand V; Villers A; Puech P; Ouzzane A
Prog Urol; 2018 Jun; 28(8-9):425-433. PubMed ID: 29789235
[TBL] [Abstract][Full Text] [Related]
17. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
Woo S; Kim SY; Lee J; Kim SH; Cho JY
Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
[TBL] [Abstract][Full Text] [Related]
20. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]